Ubiquinone and nicotinamide treatment of patients with the 3243A-->G mtDNA mutation
A M Remes1, E V Liimatta, S Winqvist
1Department of Neurology, University of Oulu, Oulu, Finland.
Abstract:
The efficacy and safety of ubiquinone (Q10) and nicotinamide were evaluated in a 6-month open-label trial in patients with the 3243A-->G mitochondrial DNA mutation. Blood lactate and pyruvate concentrations decreased, but there was little clinical improvement. Q10 and nicotinamide were well tolerated, but two patients died suddenly and unexpectedly during the trial. These deaths may have been unrelated to treatment. The unpredictable course of the disease makes evaluation of the clinical response difficult.
Related Concept Videos
Animal Mitochondrial Genetics
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
The Electron Transport Chain
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q in...
Role of Reduced Coenzymes NADH and FADH₂
Electron Transport Chain: Complex III and IV
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase


